



CENTRAL PHARMACEUTICAL CPC1.JSC

NO: 2005/CPC1-TCKT

SOCIALIST REPUBLIC OF VIETNAM
Independence – Freedom – Happiness

Re: Explanation of a Change of 10% or
More in Profit After Corporate Income Tax
in the Third Quarter of 2026 Compared with
the Third Quarter of 2025

Hanoi, 20 Oct 2026

To: - State Securities Commission of Vietnam;
- Hanoi Stock Exchange.

Pursuant to Circular No. 96/2020/TT-BTC dated November 16, 2020 of the Ministry of Finance providing guidance on information disclosure in the securities market.

Based on the Company's financial statements for the third quarters of 2026 and 2025, the Company's business performance is as follows:

- Profit after Corporate Income Tax for Q3 2026: VND 40.078 billion
- Profit after Corporate Income Tax for Q3 2025: VND 45.405 billion

Profit after corporate income tax in Q3 2026 decreased by VND 5.327 billion, representing a decrease of 11.73% compared with Q3 2025.

➤ The decrease was mainly attributable to the following factors:

- Increase in net revenue and gross profit: Net revenue in Q3 2026 increased by VND 166.290 billion, equivalent to 32.40%, compared with Q3 2025. The cost of goods sold increased by VND 137.939 billion, equivalent to 30.62%. Consequently, gross profit from sales of goods and rendering of services increased by VND 28.350 billion, equivalent to 45.18%.

- Decrease in other profit: Other profit in Q3 2026 decreased by VND 37.36 billion, representing a decrease of 107.81%, compared with Q3 2025

- Increase in financial expenses: Financial expenses in Q3 2026 increased by VND 1.143 billion, equivalent to 14.80%, compared with Q3 2025.

- Increase in selling expenses: Selling expenses in Q3 2026 increased by VND 4.971 billion, equivalent to 15.43%, compared with Q3 2025.

Taking these factors into account, profit after corporate income tax in Q3 2026 decreased by VND 5.327 billion, equivalent to 11.73%, compared with Q3 2025.

The main reason was the significant decrease in other profit, primarily attributable to a decline in compensation income from VND 37.88 billion in Q3 2025 to VND 8.19 billion in Q3 2026. In addition, increased financial expenses, particularly



interest expenses, and higher selling expenses put further pressure on profitability. Meanwhile, net operating profit increased by VND 29.17 billion, equivalent to 124.46%, supported by improvements in revenue and gross profit.

Central Pharmaceutical Joint Stock Company No.1 (CPC1) respectfully submits this explanation to the State Securities Commission of Vietnam and the Hanoi Stock Exchange for their information.

Respectfully submitted,

DEPUTY GENERAL DIRECTOR



Nguyen Huy Thanh

Recipients:

- As above;
- Filed at: Administration Office, Finance & Accounting Department, Human Resources & Administration Department.

